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Abstract Metastatic calcification, a known complication of
prolonged end-stage renal disease, is herein described for
the first time in a 10-month-old boy with acute renal failure,
manifesting as a painful and swollen arm. Imaging revealed
diffuse calcification and technetium-99 methylene
diphosphonate (
99Tc-MDP) uptake around the humerus
and axilla. Calcium and vitamin D restriction, followed by
intravenous administration of sodium thiosulfate caused a
full symptomatic, radio- and scintigraphic improvement.
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Abbreviations
ARF acute renal failure
HUS hemolytic uremic syndrome
MC metastatic calcifications
ST sodium thiosulfate
Introduction
Vascular (“metastatic”) calcification (MC) (or calcific
uremic arteriolopathy) is the most common type of extra-
osseous calcification in end stage renal disease, manifesting
as both medial and intimal calcification of large arteries [1].
It usually results from a deposition of calcified products in
otherwise normal tissues as a result of hyperphosphatemia
with or without hypercalcemia. It may affect the visceral
organs, such as kidneys, lungs, and gastric mucosa, as well
as joints, eyes, and skin [2]. The predisposing conditions of
hyperphosphatemia and high (calcium×phosphorus) con-
centration products need to be persistent over weeks and
months, since MC has been not been described in the setup
of acute renal failure (even though a similar biochemical
profile is seen there too).
We describe a case of MC in a 10-month-old child
presenting with hemolytic uremic syndrome (HUS) and
acute renal failure (ARF).
Case report
A 10-month-old male infant was recovering from his first
episode of atypical HUS. He belonged to a Bedouin tribe
previously diagnosed by us [3] with recessive factor H
deficiency. His clinical course was remarkable for micro-
angiopathic hemolytic anemia, oliguric renal failure and
hypertension with a depressed myocardial function, associ-
ated with resistant hypocalcemia (total calcium as low as
5.4 mg/dl) and hyperphosphatemia (as high as 13 mg/dl).
The latter was eventually controlled with phosphor binders
(aluminum hydroxide at first for several days and, later,
calcium gluconate), intravenous administration of calcium
(mainly due to an episode of cardiac arrest without
hyperkalemia, as previously described for HUS [4]), low
phosphorus diet and alphacalcidol, 0.25 μg q.d. (the latter
only after serum phosphorus had been normalized).
Medications were given through a right femoral vein
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Beer Sheva, Israelcatheter and peripheral veins in the right arm. Peritoneal
dialysis was started, using regular calcium (3.5 meq/l)
dialysate. Fresh frozen plasma (20 ml/kg) was given daily
until there was evidence of HUS remission, and was then
switched to 20 ml/kg twice a week, as previously done in
homozygous factor H-deficient children [5].
Ten days after hospitalization, he was found to have a
painful and mildly swollen left arm, mainly in the elbow
area, with flexion limitation. There was no intravenous
device in this arm. There were no high fever, local redness
or swollen joints. The plain X-ray did not reveal any lesions
or fractures. Aweek later the left shoulder and humeral area
were more swollen and tender, with no specific nodule or
bone deformity. On physical examination, the swelling was
deeper than the dermis (mainly in the humeral area) and
painful. The superficial skin did not show signs of
ischemia, necrosis, ulceration or livedo reticularis. This
time the plain X ray revealed diffuse calcification,
involving mostly the arm muscles and the axilla (Fig. 1a).
Calcium and phosphorus levels were 9.9 mg/dl and 6.6 mg/
dl, respectively. Renal function remained stable but im-
paired (serum creatinine and urea concentrations were as
low as 1.05 mg/dl and 90 mg/dl, respectively). Parathyroid
hormone (PTH) levels were normal (25.7 pg/ml). Renal
sonogram showed no evidence of nephrocalcinosis. A bone
scan revealed significant technetium-99 methylene
diphosphonate (
99Tc-MDP) uptake along the areas that
had seemed to be affected on the X-rays and physical
examination (Fig. 1b). Treatment with peritoneal dialysis,
alphacalcidol and calcium salts was stopped. Ketoconazole
1 mg/kg per day was given for 3 days, in addition to
prednisolone 2 mg/kg per day for a week. Renal function
improved, but the (Pi×Ca) products remained above
60 mg
2/dl
2. No improvement in the arm lesion was seen.
On day 25 of hospitalization, intravenously administered
sodium thiosulfate, 100 mg/kg q.d., was started for 12 days.
A gradual symptomatic improvement in arm range of
movement and resolution of local pain was seen. At
follow-up 8 weeks afterwards, X- ray and bone scan
revealed significant resolution of MC (Fig. 2). At long-
term (>12 months) follow-up, no recurrence of MC was
seen, in spite of recurrent events of HUS, eventually
needing periods of peritoneal and hemodialysis.
Discussion
The unique MC features in our patient were its appearance
earlyafter the diagnosis of renal failure and its transient nature.
Evidenceforsuchearlyappearanceofthiscomplicationcomes
only from an animal model of ARF (adenine-induced renal
failure in rats), where microscopic metastatic calcification in
aorta, coronary artery and other soft tissues were found after
4 weeks of uremia [6]. This was associated with hyperpara-
thyroidism, hypocalcemia and hyperphosphatemia. In addi-
tion, a high index of suspicion may detect the MC early in the
renal failure course, before it becomes ulcerated [7].
Current sophisticated imaging techniques suggest an
incidence of subclinical or asymptomatic MC in 20–100%
of patient with end-stage renal disease (ESRD) [8]. MC
with soft tissue involvement in acute renal failure, to the
best of our knowledge, has not been reported in children:
using the PubMed and MESH search systems, and the
terms “calcinosis” and “kidney failure, acute” (the term
“calciphylaxis” is not an official indexing term), we found
only three case reports of adults with such combination.
There was a combination of risk factors for MC in our
patient, including high dose parenteral calcium administra-
tion via both intravenous and peritoneal dialysis; high
serum phosphorus levels due to renal failure and the
hemolytic state; and the use of alphacalcidol [9]. These
may have led to MC so early in the course of his disease.
The possible correlation between renal failure due to HUS,
a state where the basic damage is to the endothelium in
small vessels, and MC is not supported by the literature
search. Uremic calcification was thought to be a largely
physico-chemical process facilitated by elevated Ca×P (i.e.,
“metastatic” calcification). Evidence now shows that vascu-
lar smooth muscle cells actively take up phosphate to form
bio-apatite. This process is associated with a phenotypic
transformation ofvascular smooth muscle cellsduringwhich
they express osteoblast markers [10].
Soft tissue accumulation of Tc
99m MDP may be due to
passive localization of tracer in slow fluid spaces (ascites,
pleural effusion) when the blood concentration of tracer is
high and these spaces do not clear as rapidly as the blood
pool. Tracer may also bind in necrotic tissues (myositis,
myonecrosis). Other causes of metastatic calcification
include hypercalcemia from widespread destruction of bone
(from metastatic cancer), parathyroid neoplasm and hyper-
vitaminosis D. When the solubility product of calcium and
phosphate is exceeded, there is precipitation of calcium in
the extracellular space. Soft tissue calcification is, thus,
another cause of soft tissue uptake of Tc
99m MDP [11].
Reported therapeutic strategies for treating and prevent-
ing MC include: increasing dialysis dose, lowering serum
calcium phosphorous and Ca×P solubility products, and
avoiding calcium-based Pi binders and vitamin D analogs.
Unfortunately, these methods have been ineffective in some
patients with MC. Intravenously administered sodium
thiosulfate (ST) increases the solubility of calcium deposits
[12]. ST was shown to be successful in the treatment of
both nephrolithiasis and tumoral calcinosis. ST has antiox-
idant effects on endothelial cells, but its exact mechanism
of effect is unclear. It undergoes mainly renal clearance. Its
half-life is increased from 15 min in the normal glomerular
608 Pediatr Nephrol (2007) 22:607–611filtration rate (GFR) to 478 min in dialysis-dependent
patients. The recommended adult dose is 12.5–25 g at the
end of dialysis. The duration of this treatment is unclear. In
our patient, a short ST course plus the withdrawal of enteral
calcium and vitamin D were sufficient to resolve MC,
which did not recur in the following events of HUS.
Fig. 1 Chest X-ray on day 18
(a) black arrow calcification on
the axilla, arrowheads calcifica-
tion lines along the humerus.
Tc-
99m MDP scintigraphy (b)
shows increased abnormal up-
take in the soft tissue of the left
shoulder, humerus and left
scapula. Kidneys are enlarged,
with increased diffuse abnormal
radiotracer activity
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